Loreclezole | CAS#117857-45-1 | anticonvulsant

MedKoo Cat#: 461081 | Name: Loreclezole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Loreclezole is an anticonvulsant and antiepileptic compound.

Chemical Structure

Loreclezole

CAS#117857-45-1 (free base)

Theoretical Analysis

MedKoo Cat#: 461081

Name: Loreclezole

CAS#: 117857-45-1 (free base)

Chemical Formula: C10H6Cl3N3

Exact Mass: 272.9627

Molecular Weight: 274.53

Elemental Analysis: C, 43.75; H, 2.20; Cl, 38.74; N, 15.31

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 weeks
100mg	USD 450.00	2 weeks
200mg	USD 850.00	2 weeks
500mg	USD 1,850.00	2 weeks
1g	USD 2,950.00	2 weeks
2g	USD 4,950.00	2 weeks
5g	USD 7,250.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

117857-45-1 (free base) 2227372-56-5 (HCl)

Synonym

Loreclezole; R 72063; R-72063; R72063;

IUPAC/Chemical Name

(Z)-1-(2-chloro-2-(2,4-dichlorophenyl)vinyl)-1H-1,2,4-triazole

InChi Key

XGLHZTBDUXXHOM-WMZJFQQLSA-N

InChi Code

InChI=1S/C10H6Cl3N3/c11-7-1-2-8(9(12)3-7)10(13)4-16-6-14-5-15-16/h1-6H/b10-4-

SMILES Code

ClC1=CC=C(/C(Cl)=C/N2N=CN=C2)C(Cl)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Loreclezole, an antiepileptic compound, is a selective GABAA receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors.

In vitro activity:

High concentrations of loreclezole (30 μm) inhibited PC GABA-mediated currents, as previously demonstrated with β(1) -subunit-containing GABA(A) receptors expressed in heterologous systems. Reference: Eur J Neurosci. 2013 Feb;37(4):555-63. https://pubmed.ncbi.nlm.nih.gov/23176253/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	110.0	400.69

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 274.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kelley MH, Ortiz J, Shimizu K, Grewal H, Quillinan N, Herson PS. Alterations in Purkinje cell GABAA receptor pharmacology following oxygen and glucose deprivation and cerebral ischemia reveal novel contribution of β1 -subunit-containing receptors. Eur J Neurosci. 2013 Feb;37(4):555-63. doi: 10.1111/ejn.12064. Epub 2012 Nov 26. PMID: 23176253; PMCID: PMC3772679.

In vitro protocol:

In vivo protocol:

TBD

1: Fisher JL, Hinkle DJ, Macdonald RL. Loreclezole inhibition of recombinant alpha1beta1gamma2L GABA(A) receptor single channel currents. Neuropharmacology. 2000 Jan 4;39(2):235-45. PubMed PMID: 10670419. 2: Borowicz KK, Sawiniec A, Czuczwar SJ. Interaction of loreclezole with conventional antiepileptic drugs in amygdala-kindled rats. Eur Neuropsychopharmacol. 2004 May;14(3):251-7. PubMed PMID: 15056485. 3: Borowicz KK, Czuczwar SJ. Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats. Pol J Pharmacol. 2003 Sep-Oct;55(5):727-33. PubMed PMID: 14704468. 4: Zhong Y, Simmonds MA. Interactions between loreclezole, chlormethiazole and pentobarbitone at GABA(A) receptors: functional and binding studies. Br J Pharmacol. 1997 Aug;121(7):1392-6. PubMed PMID: 9257919; PubMed Central PMCID: PMC1564829. 5: Sanna E, Murgia A, Casula A, Usala M, Maciocco E, Tuligi G, Biggio G. Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60. PubMed PMID: 9076754. 6: Ashton D, Fransen J, Heeres J, Clincke GH, Janssen PA. In vivo studies on the mechanism of action of the broad spectrum anticonvulsant loreclezole. Epilepsy Res. 1992 Mar;11(1):27-36. PubMed PMID: 1563336. 7: Donnelly JL, MacDonald RL. Loreclezole enhances apparent desensitization of recombinant GABAA receptor currents. Neuropharmacology. 1996;35(9-10):1233-41. PubMed PMID: 9014138. 8: Green AR, Misra A, Murray TK, Snape MF, Cross AJ. A behavioural and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABAA receptor. Neuropharmacology. 1996;35(9-10):1243-50. PubMed PMID: 9014139. 9: Groves JO, Guscott MR, Hallett DJ, Rosahl TW, Pike A, Davies A, Wafford KA, Reynolds DS. The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole. Eur J Neurosci. 2006 Jul;24(1):167-74. PubMed PMID: 16882014. 10: Ashton D, Willems R. In vitro studies on the broad spectrum anticonvulsant loreclezole in the hippocampus. Epilepsy Res. 1992 Apr;11(2):75-88. PubMed PMID: 1618181. 11: Wingrove PB, Wafford KA, Bain C, Whiting PJ. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4569-73. PubMed PMID: 8183949; PubMed Central PMCID: PMC43827. 12: Ates N, van Luijtelaar EL, Drinkenburg WH, Vossen JM, Coenen AM. Effects of loreclezole on epileptic activity and on EEG and behaviour in rats with absence seizures. Epilepsy Res. 1992 Oct;13(1):43-8. PubMed PMID: 1478197. 13: Rentmeester T, Hulsman J. Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients. Epilepsy Res. 1991 Mar;8(2):166-9. PubMed PMID: 2065645. 14: Xue BG, Friend JM, Gee KW. Loreclezole modulates [35S]t-butylbicyclophosphorothionate and [3H]flunitrazepam binding via a distinct site on the GABAA receptor complex. Eur J Pharmacol. 1996 Apr 4;300(1-2):125-30. PubMed PMID: 8741177. 15: Stevenson A, Wingrove PB, Whiting PJ, Wafford KA. beta-Carboline gamma-aminobutyric acidA receptor inverse agonists modulate gamma-aminobutyric acid via the loreclezole binding site as well as the benzodiazepine site. Mol Pharmacol. 1995 Dec;48(6):965-9. PubMed PMID: 8848011. 16: Ghiani CA, Tuligi G, Maciocco E, Serra M, Sanna E, Biggio G. Biochemical evaluations of the effects of loreclezole and propofol on the GABAA receptor in rat brain. Biochem Pharmacol. 1996 Jun 14;51(11):1527-34. PubMed PMID: 8630094. 17: Pohl M, Mares P. Effects of loreclezole on metrazol-induced phenomena in developing rats. Arch Int Pharmacodyn Ther. 1990 May-Jun;305:163-71. PubMed PMID: 2241426. 18: Holopainen IE, Kivelä R, Korpi ER. Do antiepileptics phenytoin, carbamazepine, and loreclezole show GABA(A) receptor subtype selectivity in rat brain sections? Neurochem Res. 2001 Jan;26(1):89-94. PubMed PMID: 11358287. 19: Rentmeester T, Janssen A, Hulsman J, Scholtes F, van der Kleij B, Overweg J, Meijer J, de Beukelaar F. Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures: a 1-year open follow-up. Epilepsy Res. 1991 May-Jun;9(1):65-70. PubMed PMID: 1909240. 20: Overweg J, De Beukelaar F. Single-dose efficacy evaluation of loreclezole in patients with photosensitive epilepsy. Epilepsy Res. 1990 Aug;6(3):227-33. PubMed PMID: 2272346.